Title
Assessment of Safety and Functional Efficacy of Stem Cell-Based Therapeutic Approaches Using Retinal Degenerative Animal Models.

Permalink
https://escholarship.org/uc/item/1bw4h77f

Journal
Stem cells international, 2017

ISSN
1687-966X

Authors
Lin, Tai-Chi
Seiler, Magdalene J
Zhu, Danhong
et al.

Publication Date
2017

DOI
10.1155/2017/9428176

Peer reviewed
Review Article

Assessment of Safety and Functional Efficacy of Stem Cell-Based Therapeutic Approaches Using Retinal Degenerative Animal Models

Tai-Chi Lin,1,2,3,4 Magdalene J. Seiler,5,6 Danhong Zhu,1,7 Paulo Falabella,1, David R. Hinton,1,7 Dennis O. Clegg,8 Mark S. Humayun,1,2 and Biju B. Thomas1,2

1Department of Ophthalmology, USC Roski Eye Institute, University of Southern California, Los Angeles, CA, USA
2USC Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA, USA
3Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan
4Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
5Stem Cell Research Center, University of California-Irvine, Irvine, CA, USA
6Department of Physical Medicine & Rehabilitation, University of California-Irvine, Irvine, CA, USA
7Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
8Center for Stem Cell Biology and Engineering, University of California, Santa Barbara, CA, USA

Correspondence should be addressed to Biju B. Thomas; biju.thomas@med.usc.edu

Received 15 April 2017; Accepted 19 June 2017; Published 27 August 2017

Academic Editor: Tilo Kunath

Copyright © 2017 Tai-Chi Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dysfunction and death of retinal pigment epithelium (RPE) and or photoreceptors can lead to irreversible vision loss. The eye represents an ideal microenvironment for stem cell-based therapy. It is considered an “immune privileged” site, and the number of cells needed for therapy is relatively low for the area of focused vision (macula). Further, surgical placement of stem cell-derived grafts (RPE, retinal progenitors, and photoreceptor precursors) into the vitreous cavity or subretinal space has been well established. In preclinical tests, assessments of stem cell-derived graft survival and functionality are conducted in animal models by various noninvasive approaches and imaging modalities. In vivo experiments conducted in animal models based on replacing photoreceptors and/or RPE cells have shown survival and functionality of the transplanted cells, rescue of the host retina, and improvement of visual function. Based on the positive results obtained from these animal experiments, human clinical trials are being initiated. Despite such progress in stem cell research, ethical, regulatory, safety, and technical difficulties still remain a challenge for the transformation of this technique into a standard clinical approach. In this review, the current status of preclinical safety and efficacy studies for retinal cell replacement therapies conducted in animal models will be discussed.

1. Introduction

Stem cell-based therapies have shown to restore or rescue visual function in preclinical models of retinal degenerative diseases [1–5] which are built on previous data with transplantation of fetal retinal tissue sheets. This has set a standard what these optimal cells can do [6–9]. Although retinal degenerative diseases such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), and Stargardt’s disease differ in their causes and demographics, all of them cause RPE and/or photoreceptor destruction which can lead to blindness [1–5]. Currently, there is no clinically accepted cure for irreversible dysfunction or death of photoreceptors and RPE. Since the retina, like other central nervous system...
tissue, has little regenerative potential [4, 10], stem cell-based therapies that aimed to replace the dysfunctional or dead cells remain a major hope.

In 1959, a rat fetal retina was transplanted into the anterior chamber of a pregnant rat’s eye [11]. Several decades later, dissociated retinal cells or cell aggregates were transplanted into the subretinal space of rats [12–17]. In the 80s, Dr. Gouras demonstrated transplantation of cultured human retinal pigment epithelial cells into the monkey retina. The transplanted cells were identified on the Bruch’s membrane by autoradiography [18]. Turner and Blair reported high survival (90–100%) and development of lamination for newborn rat retinal aggregates grafted into a lesion site of an adult rat retina [19]. Silverman and Hughes were the first one to isolate stripes of photoreceptor sheets from the postnatal and adult retina [20], and this method was modified later on by other researchers by transplanting photoreceptor sheets [21], full thickness fetal [6, 7, 22–24] or adult retina [25]. These earlier transplantation studies helped to establish “proof of concept” for future cell replacement therapies in the eye. Although the initial transplantation studies did not show any safety issues, ethical restrictions and absence of suitable animal models for preclinical evaluations delayed further progress of this approach [3]. In 2009, human embryonic stem cell- (hESC-) derived RPE cells were transplanted into Royal College of Surgeon (RCS) rats in preclinical studies [26] that eventually lead to clinical trials. Although the long-term outcomes of the preclinical investigations are not yet concluded [27–31], recent advancement in the area of induced pluripotent stem cell- (iPSC-) derived products provided a new source for transplantation. This method uses mature cells that return to a pluripotent state similar to that seen in embryonic stem cells [32–35]. Preclinical testing of iPSC-derived RPE (iPSC-RPE) cells has been established [36, 37], and human clinical trials based on iPSC-RPE have been initiated [38]. These studies indicate survival of the transplanted RPE with signs of visual functional improvement and no signs of adverse events. However, one of the first human clinical trials using autologous iPSC-RPE cells lead by Masayo Takahashi was halted for a period of time after unexpected chromosomal abnormalities were found in the second patient [39, 40]. In a different incident, severe vision loss was observed in three AMD patients after intravitreal injection of autologous adipose tissue-derived “stem cells” (https://blog.cirm.ca.gov/2017/03/15/three-people-left-blind-by-florida-clinics-unproven-stem-cell-therapy/comment-page-1/). The above report raises some concerns regarding the existing safety requirements and regulations of the use of unregulated stem cell trials [41].

In this review, current progress in stem cell-based therapies will be discussed based on safety assessments and functional evaluations conducted in various animal models of human retinal degenerative diseases.

2. Stem Cell Sources and Their Applications in the Eye

Stem cell-based therapy for RPE replacement has been initiated at various centers. Since Klimanskaya et al. developed the original protocol for hESC-derived RPE-like cells [42], various groups have used several strategies to derive RPE cells from stem cells. In earlier studies, subretinal transplantation of hESC-derived RPE (hESC-RPE) cells based on cell suspension injection was shown to rescue degenerating photoreceptors and improve vision in immunosuppressed RCS rats [26, 43]. In a more recent technique, a regenerated RPE monolayer grown on a scaffold and transplanted in immunosuppressed RCS rats showed improved survival of hESC-RPE and better clinical outcomes [44, 45] suggesting that RPE function is dependent on polarization of the transplanted RPE cells and the monolayer morphology [44–46]. iPSCs are considered to have several advantages over hESCs including protection from immune rejection, wide variety of potential sources, and reduced ethical concerns [47]. Transplantation of iPSC-RPE [37, 48] and iPSC-derived photoreceptor precursor cells [49] has demonstrated success in different animal models. The iPSC-RPE cells were shown to have morphological and functional similarities to developing and mature RPE cells in vitro and in vivo [37, 50–52]. Although it will be advantageous to use patient-derived RPE (autologous transplants), the time requirements and production cost make allograft transplantation a desirable option [47].

Patients need to have a sufficient number of surviving, functional photoreceptor cells; otherwise, replacement of only RPE will not help to rescue vision. Therefore, stem cell-derived photoreceptors [53–56] or retinal progenitor cells (RPCs) have been used with or without RPE for transplantation experiments [3, 57–60]. Previously, several types of scaffolds made of materials having different architectures, biocompatibility, size, and stiffness have been used to enhance cell survival, migration from the scaffold pores, integration into the host retina, and in vivo differentiation [61–63].

Studies have shown that the beneficial effect of RPC transplantation is likely achieved by their differentiation into functional retinal cells and subsequent replacement of lost or dysfunctional elements [64, 65]. Other investigations suggested that success of RPC transplantation is achieved through trophic factor release rather than direct replacement of the lost cells [59, 66–68]. A major challenge in incorporating photoreceptors and other neuronal cell types is the establishment of synaptic connections with the proximal neuronal elements of the recipient retina [2, 69–71]. Using transsynaptic tracing techniques and donor cell label, synaptic connections between fetal retinal sheet transplants and the host retina have been previously reported [72–74]. Replacement therapies involving the whole retina are also in progress using retinal organoids (3D retina) [70, 71, 75, 76]. Recently, hESCs and iPSCs were differentiated into optic cups and storable stratified neural retina [77, 78]. Such 3D retinal tissue derived from iPSCs or hESCs when transplanted in rd1 mice [70, 71] and immunosuppressed retinal degeneration (RD) monkeys [75] developed a structured outer nuclear layer and showed signs of synaptic formations [70, 71, 75]. The above milestone studies highlight the new concepts of regenerative medicine in retinal therapeutics emphasizing the possibility of establishing functional connections between the transplant and the host tissue.
3. Animal Models for Stem Cell-Based Therapies

Retinal degenerate rodent models have been extensively used for biomedical research, but because of the key differences between the rodent and human eye, rodent models do not completely replicate the human disease conditions. Most importantly, the rodents do not have a fovea, and in most of the rodents, the photoreceptors are mainly rod cells. Among rodent models, there are both naturally occurring diseases and transgenic animal models [84–87]. Light damage [88], laser-induced choroidal neovascularization [89], and retinotoxic agents such as sodium iodoacetate [90] and N-methyl-N-nitrosourea [91, 92] have been also used to induce retinal degenerative conditions. Among this, sodium iodate (SI) has been widely used to induce outer retinal degeneration in otherwise normal animals [93–96].

Rabbits, cats, dogs, pigs, and nonhuman primates have an eye diameter more or less similar to the human eye which allows easy testing of surgical tools and procedures developed for human patients. However, in these large animal models, inducing a disease condition similar to human patients is challenging mostly because the etiology of human diseases is multifactorial, involving both genetic and environmental contributions [1, 2]. The following section summarizes the small and large animal models that are currently used in stem cell-based research.

3.1. Mouse Models. The advantage of using mouse models is their ability to express gene mutations mimicking those identified in humans. However, dissimilarities in life span and rate of disease progression between mice and humans limit the interpretation of the disease conditions. A variety of mutations in mice can cause loss of photoreceptors and reduced rod function and hence were used as AMD models [97–103]. In humans, mutations in the Abca4 gene result in Stargardt’s disease, RP, cone-rod dystrophy, and the accumulation of lipofuscin granules in RPE, a characteristic of AMD [104, 105]. Therefore, Abca4 knockout mice which also show lipofuscin accumulation in RPE are considered a model for macular dystrophy conditions [106–110]. Mutations of the RPE65 gene in humans cause most frequently Leber congenital amaurosis, with a small percentage of severe early childhood onset retinal dystrophy [111]. Hence, Rpe65 knockout mice are a model for studying RPE65-mediated retinal dystrophy [112, 113]. Transgenic mice with a rhodopsin Pro23His (P23H) mutation that causes photoreceptor degeneration are highly comparable to human RP disease [99, 114, 115]. In humans, a gene responsible for the autosomal dominant form of Stargardt’s disease was identified recently [116, 117]. Transgenic mice harboring this defective gene (Elovl4) are considered a good model for macular degeneration diseases because of the accumulation of high levels of lipofuscin in the RPE and subsequent photoreceptor degeneration in the central retina. This disease pattern closely resembles human Stargardt’s disease and AMD [118]. Finally, there are naturally occurring mutations in mice that are used as models of RP disease inheritance [79–83]. Many of the mouse models discussed here are tested for stem cell therapies using cell suspension injections [89, 119]. In conclusion, the wide variety of gene manipulated mouse models provides a valuable tool for studies on therapeutic intervention of various forms of human RD. However, because of their small eye size, implantation of laminated sheets is found to be difficult in mice [44, 120].

3.2. Rat Models. Rats’ eyes are twice the size of mouse eyes [121] which makes it easier to perform surgical procedures [121] and transplant both fetal retinal sheets [3, 9] and RPE cells grown as a monolayer [44, 45]. The RCS rat is an animal model widely used for investigating therapeutic applications in the eye [122, 123]. The dystrophic RCS rats are characterized by RPE dysfunction due to the deletion in the Mer tyrosine kinase (Mertk) receptor that abolishes internalization of shed photoreceptor outer segments by RPE cells [124]. Accumulation of debris in the subretinal space can lead to drastic photoreceptor degeneration and rapid loss of vision. In RCS rats, the degeneration progresses slowly. At one month of age, the retinal thickness remains close to the normal level [125] and near complete photoreceptor layer thickness is present [126]. Subretinal transplantation of RPE cells derived from both iPS [127] and hESC [44, 128–130] into 21 to 28-day old RCS rats showed photoreceptor preservation and rescue of declining vision. Certain other rat models mimic the pathology and progression of RD such as the OXYS rat which spontaneously develops a phenotype similar to human aging and AMD-like pathology [131, 132]. The transgenic P23H rat (available in 3 lines with different degeneration rates), similar to P23H mouse, is frequently used as a model of studying RP diseases [85, 133]. S334ter rats carry a mutant mouse rhodopsin which leads to photoreceptor degeneration [134–136]. The five lines of this model have different characteristic rates of RD, in which S334ter line-3 and S334ter line-5 represent fast and intermediate slow degenerating models, respectively [87]. Several studies have been performed in the above rat models to assess the feasibility of retinal cell replacement therapies [3, 73, 137–141].

The advantage of using slow degeneration models is that they mimic the generally slow progression of human disease conditions. With the inner retina relatively well preserved, there is better opportunity for rescue or restoration of vision following various treatment strategies [138, 142]. However, challenges like immunological reactions and the presence of residual host photoreceptors can make it difficult to detect the transplant effects. To overcome the immunological issues, recently immunodeficient rat models (more details are provided in Section 4) are developed for testing cell-based therapies [143, 144]. In summary, rodent models are currently the leading in vivo tool for testing retinal cell therapies due to their affordable cost and easy availability [145].

3.3. Rabbit Models. Rabbits have an eye size comparable to humans and are considered a desirable model to examine therapeutic effects. However, the rabbit retina differs from that of human because it is rod-dominated and contains the visual streak, a horizontal band lying inferior to the optic nerve absent in humans [146, 147]. The densities of rods and cones in the visual streak are higher than elsewhere in the entire retina [146, 147]. Despite this difference, full-field
electroretinography (ERG) developed for the human eye can be used in the rabbit with reproducible results [148]. The transgenic TgP347L rabbit closely tracks human cone-sparing RP disease [86, 149]. Histopathological study in TgP347L rabbits reported that the retinal degeneration developed earlier in the visual streak than in other areas [86] along with some ERG abnormalities [150].

Previously, a dose-dependent correlation between the intravitreal injection of sodium iodate (SI) and retinal degeneration (RD) has been reported in rabbits [151]. According to the investigators, since injected SI may not be evenly distributed in the vitreous due to its uneven liquefaction characteristics, uneven retinal degeneration is caused. Another photoreceptor degeneration rabbit model produced by intravitreal injection of N-methyl-N-nitrosourea showed selective but inconsistent photoreceptor degeneration [152]. Subretinally injected hESC-RPE in immunosuppressed SI-induced RD rabbits failed to integrate into the areas that showed geographic atrophy-like symptoms [153]. This shortcoming was probably due to the unique features of the rabbit eye with a higher degree of immune rejection [153]. In summary, rabbits serve as a useful midsized animal model to study human diseases and therapeutics because they have large eyes compared to rodents.

3.4. Cat Models. Abyssinian cats with inherited rod-cone degeneration (rdAc model) are used as a model for studying retinal therapeutics [154, 155]. The genetic defect causative of retinal degeneration in Abyssinian cats has been identified as a single base pair change in intron 50 of the centrosomal protein 290 (CEP290) gene (IVS50+ 9T>G). This results in abnormalities in the transport and distribution of phototransduction and/or structural proteins through the connecting cilia resulting in photoreceptor degeneration [156]. A high prevalence of affected and carrier cats (45% and 44%, resp.) in the population was first observed in Sweden in 1983 [155]. The cause is speculated to be inbreeding [157]. In addition to having tapetum lucidum (discussed in the next section) which is diurnal, the human eye, a major shortcoming of this model is that it does not entirely resemble the human RP diseases where the peripheral retina is strongly abnormal compared to the central area that remain relatively less damaged. No such distinction is observed in Abyssinian cats. In this model, the degeneration is evenly distributed during the early stages where normal and diseased photoreceptors are often found side-by-side [158]. In addition, this cat model manifests a very slow progression of degeneration, taking from 12 months up to four years [154, 155, 157]. Cat breeds with faster RD disease conditions are now available [159, 160]. An early onset autosomal recessive RD disease in Persian cats was virtually completed at 16 weeks of age [160]. Another cat model, the CrxRdy cats, develops retinal thinning that initially takes place in the central retina [159]. An acute, reliable, and complete photoreceptor degeneration model in cats can be achieved by ear vein injection of high-dose iodoacetic acid [161]. Retinal sheet transplantation studies conducted in Abyssinian cats showed good signs of transplant integration with the host retina and lamination of transplant photoreceptors. However, no considerable functional improvement was noticed [162].

3.5. Dog Models. A major difference in dog eyes from that of humans is the tapetum lucidum, which is a multilayered reflective tissue of the choroid. The tapetum lucidum is interposed between the branching vessels in the choroid and the single layer of the choriocapillaris beneath the retina. The RPE cells over the tapetum lucidum are normally unpigmented. The tapetum lucidum acts to amplify and reflect light back through the photoreceptor layer again in dim light conditions [163]. Tapetum degeneration called toxic tapetopathy has been described in association with the administration of several drugs in beagle dogs [164–168]. Toxic tapetopathy is the characteristic of an altered tapetal color with degeneration or necrosis of the tapetum lucidum [164, 168]. Tapetum degeneration is not observed in the eyes of animals without a tapetum lucidum (rodents, monkeys) [164, 168] and most importantly not in humans [168].

A naturally occurring canine model of autosomal dominant RP caused by a RHO mutation was found to strongly resemble the human RP phenotype [169]. High similarity in eye size and preretinal light transmission characteristics between dogs and humans made this model suitable for examining the genetic and environmental causes of RD diseases. Previous studies demonstrated acute retinal injury in RHO mutation dogs after exposure to strong light [170, 171]. By varying the dose of light exposure, its long-term consequences including fast or slow disease progression and injury repair have been examined [170]. Although there have been no reports of stem cell-based studies conducted in these animals, this dog model can be considered a suitable candidate for future preclinical studies.

3.6. Pig Models. Several transgenic pig models have been developed for RP diseases, including the Pro347Leu transgenic pig with a rhodopsin mutation [84, 172, 173], the P347S transgenic pig [174, 175], and the P23H transgenic pig, which is considered a model for autosomal dominant RP [176]. Disease progression in most of the above models is slow, making it difficult to assess therapeutic benefits.

Several reports of cell transplantation experiments conducted in pigs are available. Rhodopsin transgenic pigs have been used for transplantation of full-thickness retina [177] and retinal progenitor cell (RPC) transplantation effects [178]. A feasibility and safety study of subretinal implantation of an hESC-RPE monolayer has been reported in immunosuppressed Yucatán minipigs [179]. This study demonstrated preservation of the outer nuclear layer and photoreceptor outer segment overlying the implant. In non-immunosuppressed pigs, adaptive immune responses were activated following allogenic iPSC-RPE transplantation [180]. The above finding suggests that immunologically matched and autologous donor cells should be considered for RPE cell replacement therapies to obviate chronic immune suppression [180].

A major advantage of using pig models is that surgical tools can be developed without much adaptation from the human parameters [1]. Previous RPE cell replacement
therapy studies conducted in pigs were focused on testing surgical feasibility of the approach rather than testing functional improvements [1, 181]. This can be also due to the absence of a suitable pig RPE dysfunction model. Although an RPE debridement model can be developed in pigs [182, 183], it is not preferred for testing RPE cell replacement therapies presumably due to both the difficulty in creating a consistent disease pattern and the severity of the trauma that could adversely affect the study outcome.

3.7. Nonhuman Primate Models. The macula is a structure of the eye unique to humans, apes, and monkeys that plays a role as the zone of greatest visual acuity. Therefore, nonhuman primates are a potentially valuable animal model for investigating macular diseases of humans [163]. AMD-like appearance could be found in rhesus monkey (Macaca mulatta), cynomolgus macaque (Macaca fascicularis), and the Japanese macaque (Macaca fuscata). This suggests that the pathogenic mechanisms and associated gene variations are common between human and nonhuman primates [184–190]. Induced RD monkey models have been reported based on systemic injection of iodoacetic acid [191] and cobalt chloride [75], fiber optic light-induced retinal damage [192, 193], and focal damage by severe light exposure [193]. However, these models hold one or more adverse features including ethical issues and inability to produce adequately sized lesions [75]. Housing, maintenance, costs, and ethical concerns due to a close evolutionary relationship to humans further make the nonhuman primate models less appealing for stem cell researchers [194, 195].

Immune rejection of allogeneic iPSC-RPE transplants was studied in cynomolgus monkeys (Macaca fascicularis) [196]. In a recent investigation, researchers used a cobalt chloride-induced retinal degeneration RP monkey model to demonstrate possible integration of hESC-derived retinal sheets with the host bipolar cells [75]. The above finding demonstrated clinical feasibility of retina sheet transplantation approach and suggests the need for developing new strategies for future clinical applications [75].

4. Tools and Approaches for In Vivo Assessment of the Transplants and Their Functionality

The eyes are one of the few paired organs in the body where it is possible that one eye is treated while the contralateral eye will serve as control. The transparent nature of the eye makes the evaluations possible through noninvasive imaging modalities.

4.1. In Vivo Imaging of Retinal Transplants and Assessment of Disease Status. Fundus imaging and fluorescein angiography are used to record baseline and follow-up examinations after stem cell therapies. Optical coherence tomography (OCT) is a noncontact, noninvasive imaging technique widely used in the clinic. The advancement of OCT technology provided rapid assessment of transplant morphology and placement location in the eye [9, 52, 197, 198]. The use of OCT imaging to assess changes in the retinal thickness post-transplantation has been established [9, 197–201]. The above studies conducted in rat models suggested that OCT is a reliable tool for in vivo screening and evaluation of retinal transplants. In our rat experiments, we observed that OCT was helpful using a novel OCT-based screening technique developed by our team. Using OCT software (Heidelberg Spectralis’s macular thickness feature), distance between the internal limiting membrane (ILM) and top of the implant was measured (Figure 1). The maximum and minimum values are recorded to determine the delta value. The delta value is obtained by subtracting the “maximum value – minimum value.” Based on the delta value, it is possible to predict whether the implant is placed flat or tilted relative to the retinal surface.

Recently, Seiler et al. [9] used a Bioptigen Envisu R2200 Spectral Domain Ophthalmic Imaging System (Bioptigen, Research Triangle Park, NC, USA) to obtain SD-OCT images of the rat retina that showed similarity between OCT and histology in the lamination pattern and thickness of the transplants (Figure 2). Other techniques like scanning laser ophthalmoscopy (SLO) can generate images from retinal
reflectance, autofluorescence, and extrinsic fluorescence. With the confocal arrangement, the SLO is capable of rejecting scattered light, thereby improving image contrast and achieving moderate depth sectioning [202]. Confocal near-infrared SLO imaging was used for in vivo detection of subretinally placed hESC-RPE implants in rats [203]. Although the lateral resolution achieved with SLO systems is comparable to that obtained with OCT, the depth resolution was relatively poor. But the advantage of SLO is the ability to detect the presence of pigments on the hESC-RPE in vivo [203]. Hence, the survival and potential functionality of an RPE graft can be established. Moreover, SLO is useful when the OCT images are difficult to interpret due to the loss of retinal architecture, as in the case of advanced AMD.

4.2. Electrophysiological Assessments. Visually evoked potentials (VEPs) have been used to determine whether the photoreceptor sheet transplants to RD rats can activate the vision recovery and connectivity by fetal retinal sheet transplantation in an immunodeficient retinal degenerate rat model, IOVS 2017;58:614–630. DOI:10.1167/iovs.15-19028; licensed under the Creative Commons attribution license.
central visual system [204]. VEPs were elicited by using strobe flash stimuli, and responses were recorded contralateral to the stimulated eye. The results showed that the reconstructed retina can produce characteristic light-evoked responses in the visual cortex [204]. Electrophysiological analysis was used to demonstrate that cortical visual function could be preserved by subretinal RPE cell grafting in RCS rats [205]. This was also established using optical imaging techniques [206]. Morphological assessments confirmed good correlation between photoreceptor survival and the extent of cortical functional preservation [206]. However, the degree of visual acuity achieved by transplants cannot be completely addressed using visually evoked cortical responses.

Electroretinography (ERG) is employed to access the diffuse electrical response of the retina. Response to flash ERG has been used to evaluate the visual functional changes in retinal degenerative animal models [43, 207, 208]. ERG assessments have revealed improved photoreceptor function in RCS rats after hESC-RPE injection [43]. A major limitation in using full-field flash ERG is that it may fail to detect signals from the comparatively small transplant area. This is because the ERG response is the cumulative effect of signals from the entire retina, whereas signal output from the transplant area may not be sufficient to generate considerable difference in the ERG wave form [9].

Focal electroretinography (fERG) is used to study a discrete region of the retina and determine if there is significantly more electrical activity in that area compared to the surrounding retina. This technique has been successfully employed in RCS rats to show photoreceptor rescue after iPSC-RPE injection [209]. Although multifocal ERG (mfERG) is also considered an equally efficient tool to analyze focal retinal changes, its application in stem cell research is still not well established. Previously, the technique has been proven to be useful in primate recordings [210] and effective in rats to show focal retinal defects [211]. However, its application in small animal studies is not very popular, presumably due to the inconsistency in the recording pattern which causes difficulties during data interpretation (unpublished observations).

Transplant functionality may be reliably assessed by means of electrophysiological mapping of the superior colliculus (SC). The SC receives direct retinal input which corresponds to the areas of the retina that are being stimulated by light [138, 212] and can provide point to point estimates of the retinal function [2]. Our previous studies have demonstrated improved SC responses in rodent models of the RD following cell-based therapies [9, 43, 137, 138, 213]. The SC mapping data can demonstrate that the quality of fetal retinal sheet transplants corresponds to the quality of the SC response [9, 214]. The transplants with more lamination shown in OCT images were later confirmed by SC electrophysiology as having better restoration of visual responses compared to those transplants that were rosetted [9] (Figure 3).

4.3. Visual Behavioral Testing. Optokinetic (OKN) testing is a noninvasive visual behavioral testing method widely used for the assessment of spatial visual acuity in rodents [3, 67, 68, 215]. The OKN response is a compensatory eye movement that reduces movement of images across the retina. Factors which affect the OKN responses are the population and distribution of surviving photoreceptors, the inner retina plasticity status, and the morphological status of subcortical visual areas of the brain like the SC [2]. The outcome of stem cell-based therapies can be assessed based on OKN responses by varying the stimulus parameters, such as grating spatial frequency and contrast sensitivity [26, 67, 68, 216]. A major advantage of the OKN testing is the ability to assess visual function without prior training of the animals. It can also enable testing of the left and right eyes independently by using a special apparatus [217] or by changing the direction of the rotation of the stimuli [218]. Previous studies demonstrated that eyes that received stem cell therapies elicit higher levels of optokinetic response compared to the control groups [43, 213, 217, 219, 220]. However, as in the case of full-field ERG, the OKN responses may be inadequate for detecting visual function from a small area showing transplant function [144]. Since the animal could see only a spot-like light from a small area in the visual field, it may fail to evoke head-tracking responses [71]. Another drawback of the OKN testing is its inability to measure higher visual processing since these responses are elicited mostly by subcortical centers. According to McGill et al. [219], since OKN responses in RD animals show conflicting results, it should be used with caution because of the subjective nature of the tests. Other techniques developed for visual behavioral testing include water maze [221, 222] and visual discrimination apparatus [223]. Although the above techniques require extensive training for the animals, they provide the opportunity to test wide variety of visual stimuli that require higher visual processing. However, these tests remain unpopular due to the training requirements, time constraints, and general concerns regarding the accuracy of two-choice tests.

5. Safety Studies for Stem Cell Transplantation Approaches

Based on some of the recent reports, the occurrence of adverse events following ocular cell replacement therapies cannot be ruled out. The first study that used autologous iPSC-RPE cells for therapy of AMD in Japan was halted after unexpected mutations were noticed in the iPSCs derived from the second patient. To overcome this issue, cord blood and samples from cord blood banks were targeted as a main source of the cells for reprogramming and a human leukocyte antigen (HLA) homozygous iPSC bank was also established [39]. The major purpose of developing this iPSC bank is to solve the issue of high cost and time consumption in processing autogenic iPSC-RPE cells [224]. There are some reports of human clinical trials based on RPE allografts that failed to survive because of immune rejection [225–227]. The degree of allografts that undergo rejection depends partly on the degree of similarity or histocompatibility between the donor and the recipient. HLA matching has great clinical impact in kidney and bone marrow transplantation but is less of a consideration in heart and lung transplantation.
Figure 3: SC recordings from RD nude rats with retinal sheet transplants. (a) Spike count totals (heat maps) over the entirety of the region recorded in SC for all transplanted rats. L: laminated transplant; R: rosetted transplant; D: disorganized transplant. Responses were observed only in certain areas in the SC and were centered on a peak. Sample traces from areas (marked with X) with robust, intermediate, and no response for (b) transplant number 5 with strong responses and (c) transplant number 1 with weak responses. Arrows and black bars indicate the light stimulus. Taken from Figure 7 of Seiler et al., vision recovery and connectivity by fetal retinal sheet transplantation in an immunodeficient retinal degenerate rat model; IOVS 2017;58:614–630. DOI:10.1167/iovs.15-19028; licensed under the Creative Commons attribution license.
Matching for HLA-B plus HLA-DR resulted in a significant correlation with graft outcome in kidney transplant patients. Grafts with no HLA-B,-DR incompatibilities had approximately 20% higher success rates at one year than grafts with 4 mismatches [230]. Sugita et al. tested all six HLA genotypes (A, B, C, DRB1, DQB1, and DPB1) and reported [228, 229].

Figure 4: Positive control experiments (injection of undifferentiated cells) conducted in athymic nude rats to show development of tumors in the eye. (a) Teratoma formation at about 6 weeks after injection (2 μl) of undifferentiated hESCE suspension (60,000 cells/μl) shown on H&E staining (2x) (arrowhead: lens, arrow: tumor formation originated from the subretinal space, broken arrow: the margin of the tumor). (b) 10x magnification of the black square from (a). The teratoma is composed of various cell types, including cartilage cells (arrowhead).

Figure 5: Genotyping assays of immunodeficient S334ter-3 rats. (a) S334ter transgene genotyping assay. Lane 1 15 bp–3 kb size marker. Lane 2 transgene-negative sample. Lane 3 transgene-positive sample. Sizes in base pairs (bp) are indicated to the left of the image. An amplicon of 350 bp indicates the presence of the transgene. The 15- and 3000-bp alignment markers are present in all lanes. (b) Allelic discrimination assay plot for detection of the Foxn1rnu mutation. The fluorescence levels of VIC (wild type, allele X) and FAM (mutant, allele Y) are plotted on the x-axis and y-axis, respectively. The genotypes of each sample are represented by blue diamonds (homozygous Foxn1rnu), red circles (homozygous for the wild-type Foxn1 allele), or green triangles (heterozygous +/Foxn1rnu). The no template negative control is represented by the gray box. Reprinted from Graefes Arch Clin Exp Ophthalmol, vol. 252, Seiler et al., a new immunodeficient pigmented retinal degenerate rat strain to study transplantation of human cells without immunosuppression, pages 1079–1092, copyright (2014), with permission from Elsevier. DOI 10.1007/s00417-014-2638-y.
that the effector T cells can recognize MHC molecules on the allogeneic iPSC-RPE cells, but the immune reaction caused by the T cells can be prevented after HLA blood tests [224]. Therefore, the future clinical trials can make use of allogeneic RPE cells derived from iPSC lines procured from the HLA-homozygous iPSC bank [39, 224]. Nevertheless, further detailed analysis is needed using larger sample size and long-term follow-up [224].

In a recent report, three AMD patients in Florida suffered severe vision loss after receiving injection of autologous adipose tissue-derived stem cells. In this study, adipose-derived stem cells were injected into the eye based on minimal clinical evidence of safety or efficacy. The injection caused ocular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined traction and rhegmatogenous retinal detachment, and lens dislocation [41].

The major concern of optimum safety and purity of the cells is that the products should be free of undifferentiated cells and should demonstrate the genetic and functional signature of the desired stem cell-derived tissue. Undifferentiated pluripotent stem cells have the capacity to differentiate into all cell types of the three germ layers and may cause tumor formation. Therefore, extensive testing for the absence of tumor formation and cell migration before implantation is crucial [2]. Differentiation into undesired cell types is a potential threat to the success of stem cell-derived cell therapies. Confirming the purity of stem cell derivations before transplantation is mandatory [231]. In one study, subcutaneous transplantation of iPSCs into immunosuppressed mice resulted in tumor formation, demonstrating the pluripotency of the injected iPSCs and its capability to evade immune detection [232]. The ability of tumor formation is often assessed using tumorigenicity studies in animal models. According to Nazari et al. [2], assessing tumorigenicity potential in immunocompetent animal models can be misleading since the absence of tumor formation might be
related to the ability of the host to reject tumorigenic cells before tumors form. However, this can be overcome by using positive controls (injection of undifferentiated cells) that are expected to develop tumors in the target area (Figure 4).

Although the eye is to a large extent regarded as an immune privileged organ, there is strong evidence for immune response to xenografts [199, 233–235]. When disease models are used for assessing functional efficacy, immunosuppressant drugs are administered to avoid immunological rejection. Most of the preclinical studies involving human-derived cells used animal models that are exposed to severe immunosuppression regimes [26, 196]. Administration of immunosuppressants in rodents is labor intensive and may cause additional pain and discomfort to the animals. A recent study demonstrated more adverse effects of immunosuppression in animal models. Cyclosporine A plus dexamethasone-administered RCS rats showed depressed scores on visual behavioral and electrophysiological testing [236]. To overcome the above issues, we have developed new immunodeficient rat models. This was accomplished by crossing between nondystrophic immunodeficient animals (NIH nude rats) and RD disease models. The double homozygous pups (immunodeficient RD) can be determined by genotyping [143, 144]. Based on this, an immunodeficient S334ter-line-3 rat colony has been established which eliminated the need for immunosuppression when transplanting xenografts [143] (Figure 5). More recently, a new immunodeficient RCS rat model has been also created [144] and is currently being tested for various stem cell-based products (Figure 6). By employing these models, it is possible to justify ethical concerns by reducing animal use and the overall study cost can be considerably lowered.

6. Conclusion

Stem cell-based therapies provide a new treatment option for retinal degenerative diseases that were previously considered incurable. Preclinical experiments conducted in animal disease models demonstrated functional efficacy and safety of ocular cell replacement therapies. Studies conducted in large animal models helped to establish the surgical techniques required for clinical trials. The above animal studies have paved the way for several clinical trials based on cell-based therapies currently in progress.

Conflicts of Interest

Magdalene J. Seiler has proprietary interest in the instrument and method for transplanting retinal sheets (Ocular Transplantation LLC). Mark S. Humayun, David R. Hinton, and Dennis O. Clegg are cofounders and consultants to Regenerative Patch Technologies (RPT). The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

This study was supported by the CIRM (Magdalene J. Seiler, Mark S. Humayun, David R. Hinton, and Dennis O. Clegg), Bright Focus Foundation (Biju B. Thomas), and Research to Prevent Blindness (USC Roski Eye Institute). The authors thank Dr. Robert Aramant (UCI, Stem Cell Research Center; Ocular Transplantation LLC, Crestwood, KY) for his helpful comments to the article and his contributions to retinal sheet transplant research. Work shown in the figures was made possible by Xiaopeng Wang (USC), Bin Lin, Ph.D., Bryce McLelland, B.S., and Anu Mathur M.S. (UC Irvine, Stem Cell Research Center).

References

[1] M. K. Jones, B. Lu, S. Girman, and S. Wang, “Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases,” Progress in Retinal and Eye Research, vol. 58, pp. 1–27, 2017.
[2] H. Nazari, L. Zhang, D. Zhu et al., “Stem cell based therapies for age-related macular degeneration: the promises and the challenges,” Progress in Retinal and Eye Research, vol. 48, pp. 1–39, 2015.
[3] M. J. Seiler and R. B. Aramant, “Cell replacement and visual restoration by retinal sheet transplants,” Progress in Retinal and Eye Research, vol. 31, no. 6, pp. 661–687, 2012.
[4] J. D. Sengillo, S. Justus, Y. T. Tsai, T. Cabral, and S. H. Tsang, “Gene and cell-based therapies for inherited retinal disorders: an update,” American Journal of Medical Genetics Part C, Seminars in Medical Genetics, vol. 172, no. 4, pp. 349–366, 2016.
[5] M. Zarbin, “Cell-based therapy for degenerative retinal disease,” Trends in Molecular Medicine, vol. 22, no. 2, pp. 115–134, 2016.
[6] M. J. Seiler and R. B. Aramant, “Intact sheets of fetal retina transplanted to restore damaged rat retinas,” Investigative Ophthalmology & Visual Science, vol. 39, no. 11, pp. 2121–2131, 1998.
[7] R. B. Aramant, M. J. Seiler, and S. L. Ball, “Successful cotransplantation of intact sheets of fetal retina with retinal pigment epithelium,” Investigative Ophthalmology & Visual Science, vol. 40, no. 7, pp. 1557–1564, 1999.
[8] N. D. Radtke, R. B. Aramant, H. M. Petry, P. T. Green, D. J. Pidwell, and M. J. Seiler, “Vision improvement in retinal degeneration patients by implantation of retina together with retinal pigment epithelium,” American Journal of Ophthalmology, vol. 146, no. 2, pp. 172–182, 2008.
[9] M. J. Seiler, R. E. Lin, B. T. McLelland et al., “Vision recovery and connectivity by fetal retinal sheet transplantation in an immunodeficient retinal degenerate rat model,” Investigative Ophthalmology & Visual Science, vol. 58, no. 1, pp. 614–630, 2017.
[10] A. Dahlmann-Noor, S. Vijay, H. Jayaram, A. Limb, and P. T. Khaw, “Current approaches and future prospects for stem cell rescue and regeneration of the retina and optic nerve,” Canadian Journal of Ophthalmology, vol. 45, no. 4, pp. 333–341, 2010.
[11] P. E. Royo and W. B. Quay, “Retinal transplantation from fetal to maternal mammalian eye,” Growth, vol. 23, pp. 313–336, 1959.
[12] M. del Cerro, H. H. Yeh, A. Marrero-Rodriguez, E. Lazar, and C. del Cerro, “Intracocular transplantation of cell layers derived from neonatal rat retina,” Brain Research, vol. 535, no. 1, pp. 25–32, 1990.
[13] R. Aramant, M. Seiler, B. Ehinger et al., “Transplantation of human embryonic retina to adult rat retina,” *Restorative Neurology and Neuroscience*, vol. 2, no. 1, pp. 9–22, 1990.

[14] M. del Cerro, J. R. Ison, G. P. Bowen, E. Lazar, and C. del Cerro, “Intraretinal grafting restores visual function in light-blinded rats,” *Neuroreport*, vol. 2, no. 9, pp. 529–532, 1991.

[15] P. Gouras, J. Du, M. Gelanze, R. Kwun, H. Kjeldbye, and R. Lopez, “Transplantation of photoreceptors labeled with tritiated thymidine into RCS rats,” *Investigative Ophthalmology & Visual Science*, vol. 32, no. 5, pp. 1704–1707, 1991.

[16] R. Aramant and M. Seiler, “Cryopreservation and transplantation of immature rat retina into adult rat retina,” *Brain Research Developmental Brain Research*, vol. 61, no. 2, pp. 151–159, 1991.

[17] R. B. Aramant and M. J. Seiler, “Human embryonic retinal cell transplants in athymic immunodeficient rat hosts,” *Cell Transplantation*, vol. 3, no. 6, pp. 461–474, 1994.

[18] P. Gouras, M. T. Flood, and H. Kjeldbye, “Transplantation of cultured human retinal cells to monkey retina,” *Anais da Academia Brasileira de Ciencias*, vol. 56, no. 4, pp. 431–443, 1984.

[19] J. E. Turner and J. R. Blair, “Newborn rat retinal cells transplanted into a retinal lesion site in adult host eyes,” *Brain Research*, vol. 391, no. 1, pp. 91–104, 1986.

[20] M. S. Silverman and S. E. Hughes, “Transplantation of photoreceptors to light-damaged retina,” *Investigative Ophthalmology & Visual Science*, vol. 30, no. 8, pp. 1684–1690, 1989.

[21] S. Mohand-Said, D. Hicks, M. Simonutti et al., “Photoreceptor transplants increase host cone survival in the retinal degeneration (rd) mouse,” *Ophthalmic Research*, vol. 29, no. 5, pp. 290–297, 1997.

[22] R. B. Aramant and M. J. Seiler, “Transplanted sheets of human retina and retinal pigment epithelium develop normally in nude rats,” *Experimental Eye Research*, vol. 75, no. 2, pp. 115–125, 2002.

[23] F. Ghosh, K. Arner, and B. Ehinger, “Transplant of full-thickness embryonic rabbit retina using pars plana vitrectomy,” *Retina (Philadelphia, Pennsylvania)*, vol. 18, no. 2, pp. 136–142, 1998.

[24] F. Ghosh, B. Juliusson, K. Arner, and B. Ehinger, “Partial and full-thickness neuroretinal transplants,” *Experimental Eye Research*, vol. 68, no. 1, pp. 67–74, 1999.

[25] J. Wasselius and F. Ghosh, “Adult rabbit retinal transplants,” *Investigative Ophthalmology & Visual Science*, vol. 42, no. 11, pp. 2632–2638, 2001.

[26] B. Lu, C. Macleit, S. Wang et al., “Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration,” *Stem Cells (Dayton, Ohio)*, vol. 27, no. 9, pp. 2126–2135, 2009.

[27] E. Lee and R. E. MacLaren, “Sources of retinal pigment epithelium (RPE) for replacement therapy,” *The British Journal of Ophthalmology*, vol. 95, no. 4, pp. 445–449, 2011.

[28] B. Lu, D. Zhu, D. Hinton, M. S. Humayun, and Y. C. Tai, “Mesh-supported submicron parylene-C membranes for culturing retinal pigment epithelial cells,” *Biomedical Microdevices*, vol. 14, no. 4, pp. 659–667, 2012.

[29] S. D. Schwartz, J. P. Hubschman, G. Heilwell et al., “Embryonic stem cell trials for macular degeneration: a preliminary report,” *Lancet*, vol. 379, no. 9817, pp. 713–720, 2012.

[30] S. D. Schwartz, C. D. Regillo, B. I. Lam et al., “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies,” *Lancet*, vol. 385, no. 9967, pp. 509–516, 2015.

[31] S. D. Schwartz, G. Tan, H. Hosseini, and A. Nagiel, “Subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium for the treatment of macular degeneration: an assessment at 4 years,” *Investigative Ophthalmology & Visual Science*, vol. 57, no. 5, pp. ORSFc1–ORSFc9, 2016.

[32] T. Aoi, K. Yae, M. Nakagawa et al., “Generation of pluripotent stem cells from adult mouse liver and stomach cells,” *Science*, vol. 321, no. 5889, pp. 699–702, 2008.

[33] J. Hanna, S. Markoula, P. Schorderet et al., “Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency,” *Cell*, vol. 133, no. 2, pp. 250–264, 2008.

[34] K. Takahashi, K. Okita, M. Nakagawa, and S. Yamanaka, “Induction of pluripotent stem cells from fibroblast cultures,” *Nature Protocols*, vol. 2, no. 12, pp. 3081–3089, 2007.

[35] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” *Cell*, vol. 131, no. 5, pp. 861–872, 2007.

[36] S. Okamoto and M. Takahashi, “Induction of retinal pigment epithelial cells from monkey iPS cells,” *Investigative Ophthalmology & Visual Science*, vol. 52, no. 12, pp. 8785–8790, 2011.

[37] Y. Li, Y. T. Tsai, C. W. Hsu et al., “Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa,” *Molecular Medicine*, vol. 18, pp. 1312–1319, 2012.

[38] A. Garg, J. Yang, W. Lee, and S. H. Tsang, “Stem cell therapies in retinal disorders,” *Cell*, vol. 6, no. 1, 2017.

[39] D. Ilic, “iPSC in the past decade: the Japanese dominance,” *Regenerative Medicine*, vol. 11, no. 8, pp. 747–749, 2016.

[40] N. Wu and M. Doorenbos, “Induced pluripotent stem cells: development in the ophthalmologic field,” *Stem Cells International*, vol. 2016, Article ID 2361763, 7 pages, 2016.

[41] A. E. Kuriyan, T. A. Albini, J. H. Townsend et al., “Vision loss after intravitreal injection of autologous ‘stem cells’ for AMD,” *The New England Journal of Medicine*, vol. 376, no. 11, pp. 1047–1053, 2017.

[42] I. Klimanskaya, J. Hipp, K. A. Rezai, M. West, A. Atala, and R. Lanza, “Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells using transriptomics,” *Cloning and Stem Cells*, vol. 6, no. 3, pp. 217–245, 2004.

[43] R. D. Lund, S. Wang, I. Klimanskaya et al., “Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats,” *Cloning Stem Cells*, vol. 8, no. 3, pp. 189–199, 2006.

[44] B. Diniz, P. Thomas, B. Thomas et al., “Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer,” *Investigative Ophthalmology & Visual Science*, vol. 54, no. 7, pp. 5087–5096, 2013.

[45] B. B. Thomas, D. Zhu, L. Zhang et al., “Survival and functionality of hESC-derived retinal pigment epithelium cells cultured as a monolayer on polymer substrates transplanted in RCS rats,” *Investigative Ophthalmology & Visual Science*, vol. 57, no. 6, pp. 2877–2887, 2016.
D. A. Lamba, M. O. Karl, C. B. Ware, and T. A. Reh, "Efficient generation of retinal progenitor cells from human embryonic stem cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 34, pp. 12769–12774, 2006.

B. A. Tucker, S. M. Redenti, C. Jiang et al., "The use of progenitor cell/biodegradable MMP2–PLGA polymer constructs to enhance cellular integration and retinal repopulation," *Biomaterials*, vol. 31, no. 1, pp. 9–19, 2010.

S. Tao, C. Young, S. Redenti et al., "Survival, migration and differentiation of retinal progenitor cells transplanted on micro-machined poly(methyl methacrylate) scaffolds to the subretinal space," *Lab on a Chip*, vol. 7, no. 6, pp. 695–701, 2007.

K. E. Kador and J. L. Goldberg, "Scaffolds and stem cells: delivery of cell transplants for retinal degenerations," *Expert Review of Ophthalmology*, vol. 7, no. 5, pp. 459–470, 2012.

H. Klassen, J. F. Kiilgaard, T. Zahir et al., "Progenitor cells from the porcine neural retina express photoreceptor markers after transplantation to the subretinal space of allogeneic recipients," *Stem Cells (Dayton, Ohio)*, vol. 25, no. 5, pp. 1222–1230, 2007.

K. Warvinge, J. F. Kiilgaard, E. B. Lavik et al., "Retinal progenitor cell xenografts to the pig retina: morphologic integration and cytochemical differentiation," *Archives of Ophthalmology*, vol. 123, no. 10, pp. 1385–1393, 2005.

R. D. Lund, S. Wang, B. Lu et al., "Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease," *Stem Cells (Dayton, Ohio)*, vol. 25, no. 3, pp. 602–611, 2007.

R. D. Lund, P. Adamson, Y. Sauve et al., "Subretinal transplantation of genetically modified human cell lines attenuates loss of visual function in dystrophic rats," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 17, pp. 9942–9947, 2001.

R. D. Lund, A. S. Kwan, D. J. Keegan, Y. Sauve, P. J. Coffey, and J. M. Lawrence, "Cell transplantation as a treatment for retinal disease," *Progress in Retinal and Eye Research*, vol. 20, no. 4, pp. 415–449, 2001.

A. Gonzalez-Cordero, E. L. West, R. A. Pearson et al., "Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina," *Nature Biotechnology*, vol. 31, no. 8, pp. 741–747, 2013.

J. Assawachananont, M. Mandal, S. Okamoto et al., "Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice," *Stem Cells Reports*, vol. 2, no. 5, pp. 662–674, 2014.

M. Mandal, M. Fuji, T. Hashiguchi et al., "iPSC-derived retina transplants improve vision in rd1 end-stage retinal-degeneration mice," *Stem Cells Reports*, vol. 8, no. 1, pp. 69–83, 2017.

M. J. Seiler, B. T. Sagdullaev, G. Woch, B. B. Thomas, and R. B. Aramant, "Transsynaptic virus tracing from host brain to subretinal transplants," *The European Journal of Neuroscience*, vol. 21, no. 1, pp. 161–172, 2005.

M. J. Seiler, B. B. Thomas, Z. Chen, R. Wu, S. R. Sadda, and R. B. Aramant, "Retinal transplants restore visual responses: trans-synaptic tracing from visually responsive sites labels transplant neurons," *The European Journal of Neuroscience*, vol. 28, no. 1, pp. 208–220, 2008.

M. J. Seiler, R. B. Aramant, B. B. Thomas, Q. Peng, S. R. Sadda, and H. S. Keirstead, "Visual restoration and transplant connectivity in degenerate rats implanted with retinal progenitor sheets," *The European Journal of Neuroscience*, vol. 31, no. 3, pp. 508–520, 2010.
[75] H. Shirai, M. Mandai, K. Matsushita et al., “Transplantation of human embryonic stem cell-derived retinal tissue in two primate models of retinal degeneration,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 113, no. 1, pp. E81–E90, 2016.

[76] D. M. Gamm, M. J. Phillips, and R. Singh, “Modeling retinal degenerative diseases with human iPSC-derived cells: current status and future implications,” vol. 8, no. 3, pp. 213–216, 2013.

[77] T. Nakano, S. Ando, N. Takata et al., “Self-formation of optic cups and storable stratified neural retina from human ESCs,” *Cell Stem Cell*, vol. 10, no. 6, pp. 771–785, 2012.

[78] X. Zhong, C. Gutierrez, T. Xue et al., “Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs,” *Nature Communications*, vol. 5, p. 4047, 2014.

[79] M. E. McLaughlin, M. A. Sandberg, E. L. Berson, and T. P. Dryja, “Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa,” *Nature Genetics*, vol. 4, no. 2, pp. 130–134, 1993.

[80] C. H. Sung, C. Makino, D. Baylor, and J. Nathans, “A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment,” *The Journal of Neuroscience*, vol. 14, no. 10, pp. 5818–5833, 1994.

[81] M. Frasson, J. A. Sahel, M. Fabre, M. Simonutti, H. Dreyfus, and S. Picaud, “Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse,” *Nature Medicine*, vol. 5, no. 10, pp. 1183–1187, 1999.

[82] A. J. Jimenez, J. M. Garcia-Fernandez, B. Gonzalez, and R. G. Foster, “The spatio-temporal pattern of photoreceptor degeneration in the aged rd/rd mouse retina,” *Cell and Tissue Research*, vol. 284, no. 2, pp. 193–202, 1996.

[83] B. Chang, N. L. Hawes, M. T. Pardue et al., “Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene,” *Vision Research*, vol. 47, no. 5, pp. 624–633, 2007.

[84] Z. Y. Li, F. Wong, J. H. Chang et al., “Rhodopsin transgenic pigs as a model for human retinitis pigmentosa,” *Investigative Ophthalmology & Visual Science*, vol. 39, no. 5, pp. 808–819, 1998.

[85] S. Machida, M. Kondo, J. A. Jamison et al., “P23H rhodopsin transgenic rat: correlation of retinal function with histopathology,” *Investigative Ophthalmology & Visual Science*, vol. 41, no. 10, pp. 3200–3209, 2000.

[86] M. Kondo, T. Sakai, K. Komeima et al., “Generation of a transgenic rabbit model of retinal degeneration,” *Investigative Ophthalmology & Visual Science*, vol. 50, no. 3, pp. 1371–1377, 2009.

[87] G. Martinez-Navarrete, M. J. Seiler, R. B. Aramant, L. Fernandez-Sanchez, I. Pinilla, and N. Cuenca, “Retinal degeneration in two lines of transgenic S334ter rats,” *Experimental Eye Research*, vol. 92, no. 3, pp. 227–237, 2011.

[88] D. T. Organisciak and D. K. Vaughan, “Retinal light damage: mechanisms and protection,” *Progress in Retinal and Eye Research*, vol. 29, no. 2, pp. 113–134, 2010.

[89] R. S. Shah, B. T. Soetikno, M. Lajko, and A. A. Fawzi, “A mouse model for laser-induced choroidal neovascularization,” *Journal of Visualized Experiments*, vol. 106, article e53502, 2015.

[90] C. Graymore and K. Tansley, “Iodoacetate poisoning of the rat retina. I. Production of retinal degeneration,” *The British Journal of Ophthalmology*, vol. 43, no. 3, pp. 177–185, 1959.

[91] Y. Y. Chen, S. L. Liu, D. P. Hu, Y. Q. Xing, and Y. Shen, “N -methyl- N -nitrosourea-induced retinal degeneration in mice,” *Experimental Eye Research*, vol. 121, pp. 102–113, 2014.

[92] A. Tsubura, K. Yoshizawa, M. Kuwata, and N. Uehara, “Animal models for retinitis pigmentosa induced by MNU; disease progression, mechanisms and therapeutic trials,” *Histology and Histopathology*, vol. 25, no. 7, pp. 933–944, 2010.

[93] A. Sorsby, “Experimental pigmentary degeneration of the retina by sodium iodate,” *The British Journal of Ophthalmology*, vol. 25, no. 2, pp. 58–62, 1941.

[94] K. Kiuchi, K. Yoshizawa, N. Shikata, K. Moriguchi, and A. Tsubura, “Morphologic characteristics of retinal degeneration induced by sodium iodate in mice,” *Current Eye Research*, vol. 25, no. 6, pp. 373–379, 2002.

[95] V. Enzmann, B. W. Row, Y. Yamauchi et al., “Behavioral and anatomical abnormalities in a sodium iodate-induced model of retinal pigment epithelium degeneration,” *Experimental Eye Research*, vol. 82, no. 3, pp. 441–448, 2006.

[96] M. Carido, Y. Zhu, K. Postel et al., “Characterization of a mouse model with complete RPE loss and its use for RPE cell transplantation,” *Investigative Ophthalmology & Visual Science*, vol. 55, no. 8, pp. 5431–5444, 2014.

[97] S. Dithmar, C. A. Curcio, Le NA, S. Brown, and H. E. Grossniklaus, “Ultrastructural changes in Bruch’s membrane of apolipoprotein E-deficient mice,” *Investigative Ophthalmology & Visual Science*, vol. 41, no. 8, pp. 2035–2042, 2000.

[98] J. Ambati, A. Anand, S. Fernandez et al., “An animal model of age-related macular degeneration in senescent Ccl2- or Ccr2-deficient mice,” *Nature Medicine*, vol. 9, no. 11, pp. 1390–1397, 2003.

[99] M. Rudolf, B. Winkler, Z. Aherrahou, L. C. Doehring, P. Kaczmarek, and U. Schmidt-Erfurth, “Increased expression of vascular endothelial growth factor associated with accumulation of lipids in Bruch’s membrane of LDL receptor knockout mice,” *The British Journal of Ophthalmology*, vol. 89, no. 12, pp. 1627–1630, 2005.

[100] Y. Imamura, S. Noda, K. Hashizume et al., “Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 30, pp. 11282–11287, 2006.

[101] J. Tuo, C. M. Bojanowski, M. Zhou et al., “Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration,” *Investigative Ophthalmology & Visual Science*, vol. 48, no. 8, pp. 3827–3836, 2007.

[102] U. F. Luhmann, S. Robbie, P. M. Munro et al., “The drusen-like phenotype in aging Ccl2-knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages,” *Investigative Ophthalmology & Visual Science*, vol. 50, no. 12, pp. 5934–5943, 2009.

[103] Z. Zhao, Y. Chen, J. Wang et al., “Age-related retinopathy in Nrf2-deficient mice,” *PLOS One*, vol. 6, no. 4, article e19456, 2011.

[104] R. Allikmets, “Simple and complex ABCR: genetic predisposition to retinal disease,” *American Journal of Human Genetics*, vol. 67, no. 4, pp. 793–799, 2000.
[105] F. P. Cremers, D. J. van de Pol, M. van Driel et al., “Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site mutations in the Stargardt’s disease gene ABCR,” Human Molecular Genetics, vol. 7, no. 3, pp. 355–362, 1998.

[106] R. Allikmets, N. Singh, H. Sun et al., “A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy,” Nature Genetics, vol. 15, no. 3, pp. 236–246, 1997.

[107] J. Weng, N. L. Mata, S. M. Azarian, J. W. Gordon, B. S. Pawlyk et al., “Insights into the function of Rim protein in photoreceptors and etiology of Stargardt’s disease from the phenotype in abcr knockout mice,” Cell, vol. 98, no. 1, pp. 13–23, 1999.

[108] N. L. Mata, J. Weng, and G. H. Travis, “Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 7154–7159, 2000.

[109] N. F. Shroyer, R. A. Lewis, A. N. Yatsenko, T. G. Wensel, and J. R. Lupski, “Coexpression and functional analysis of mutant ABCR (ABCA4) alleles in families that manifest both Stargardt disease and age-related macular degeneration,” Human Molecular Genetics, vol. 10, no. 23, pp. 2671–2678, 2001.

[110] P. Charbel Issa and A. R. Barnard, “Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 27, pp. 8415–8420, 2015.

[111] R. G. Weleber, M. Michaelides, K. M. Trzupek, N. B. Stover, and E. M. Stone, “The phenotype of severe early childhood onset retinal dystrophy (SECORD) from mutation of RPE65 and differentiation from Leber congenital amaurosis,” Investigative Ophthalmology & Visual Science, vol. 52, no. 1, pp. 292–302, 2011.

[112] B. Rohrer, P. Goletz, S. Znoiko et al., “Correlation of regenerable opsin with rod ERG signal in Rpe65−/− mice during development and aging,” Investigative Ophthalmology & Visual Science, vol. 44, no. 1, pp. 310–315, 2003.

[113] S. L. Znoiko, B. Rohrer, K. Lu, H. R. Lohr, R. K. Crouch, and J. X. Ma, “Downregulation of cone-specific gene expression and degeneration of cone photoreceptors in the Rpe65−/− mouse at early ages,” Investigative Ophthalmology & Visual Science, vol. 46, no. 4, pp. 1473–1479, 2005.

[114] J. E. Olsson, J. W. Gordon, B. S. Pawlyk et al., “Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa,” Neuron, vol. 9, no. 5, pp. 815–830, 1992.

[115] A. S. Lewin, B. Rossomiller, and H. Mao, “Gene augmentation for adRP mutations in RHO,” Cold Spring Harbor Perspectives in Medicine, vol. 4, no. 9, article a017400, 2014.

[116] K. Zhang, M. Kniazeva, M. Han et al., “A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy,” Nature Genetics, vol. 27, no. 1, pp. 89–93, 2001.

[117] A. O. Edwards, L. A. Donoso, and R. Ritter 3rd, “A novel gene for autosomal dominant Stargardt-like macular dystrophy with homology to the SUR4 protein family,” Investigative Ophthalmology & Visual Science, vol. 42, no. 11, pp. 2652–2663, 2001.

[118] G. Karan, C. Lillo, Z. Yang et al., “Lipofuscin accumulation, abnormal electrophysiology, and photoreceptor degeneration in mutant ELOVL4 transgenic mice: a model for macular degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 11, pp. 4164–4169, 2005.

[119] P. D. Westenskow, T. Kurihara, S. Bravo et al., “Performing subretinal injections in rodents to deliver retinal pigment epithelium cells in suspension,” Journal of Visualized Experiments, vol. 95, article 52247, 2015.

[120] S. Arai, B. B. Thomas, M. J. Seiler et al., “Restoration of visual responses following transplantation of intact retinal sheets in rd mice,” Experimental Eye Research, vol. 79, no. 3, pp. 331–341, 2004.

[121] S. Remtulla and P. E. Hallett, “A schematic eye for the mouse, and comparisons with the rat,” Vision Research, vol. 25, no. 1, pp. 21–31, 1985.

[122] P. M. D’Cruz, D. Yasumura, J. Weir et al., “Mutation of the receptor tyrosine kinase gene Merk in the retinal dystrophic RCS rat,” Human Molecular Genetics, vol. 9, no. 4, pp. 645–651, 2000.

[123] D. Vollrath, W. Feng, J. I. Duncan et al., “Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Merk,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 22, pp. 12584–12589, 2001.

[124] E. F. Nandrot and E. M. Dufour, “Merk in daily retinal phagocytosis: a history in the making,” Advances in Experimental Medicine and Biology, vol. 664, pp. 133–140, 2010.

[125] G. Li, B. De La Garza, Y. Y. Shih, E. R. Muir, and T. Q. Duong, “Layer-specific blood-flow MRI of retinitis pigmentosa in RCS rats,” Experimental Eye Research, vol. 101, pp. 90–96, 2012.

[126] T. J. McGill, R. M. Douglas, R. D. Lund, and G. T. Prusky, “Quantification of spatial vision in the Royal College of Surgeons rat,” Investigative Ophthalmology & Visual Science, vol. 45, no. 3, pp. 932–936, 2004.

[127] A. J. Carr, A. A. Vugler, S. T. Hikita et al., “Protective effects of human iPSc-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat,” PLoS One, vol. 4, no. 12, article e8152, 2009.

[128] I. Pinilla, N. Cuenca, Y. Sauve, S. Wang, and R. D. Lund, “Preservation of outer retina and its synaptic connectivity following subretinal injections of human RPE cells in the Royal College of Surgeons rat,” Experimental Eye Research, vol. 85, no. 3, pp. 381–392, 2007.

[129] S. Wang, B. Lu, S. Girman, T. Holmes, N. Bischoff, and R. D. Lund, “Morphological and functional rescue in RCS rats after RPE cell line transplantation at a later stage of degeneration,” Investigative Ophthalmology & Visual Science, vol. 49, no. 1, pp. 416–421, 2008.

[130] U. C. Park, M. S. Cho, J. H. Park et al., “Subretinal transplantation of putative retinal pigment epithelial cells derived from human embryonic stem cells in rat retinal degeneration model,” Clinical and Experimental Reproductive Medicine, vol. 38, no. 4, pp. 216–221, 2011.

[131] O. S. Kozhevnikova, E. E. Korbolina, N. I. Ershov, and N. G. Kolosova, “Rat retinal transcriptome: effects of aging and AMD-like retinopathy,” Cell Cycle, vol. 12, no. 11, pp. 1745–1761, 2013.

[132] A. M. Markovets, V. B. Saprunova, A. A. Zhdkanka, A. Fursova, L. E. Bakeeva, and N. G. Kolosova, “Alterations...
of retinal pigment epithelium cause AMD-like retinopathy in senescence-accelerated OXYS rats,” Aging (Albany, New York), vol. 3, no. 1, pp. 44–54, 2011.

[133] N. Cuenca, I. Pinilla, Y. Sauve, B. Lu, S. Wang, and R. D. Lund, “Regressive and reactive changes in the connectivity patterns of rod and cone pathways of P23H transgenic rat retina,” Neurosciences, vol. 127, no. 2, pp. 301–317, 2004.

[134] C. Liu, Y. Li, M. Peng, A. M. Laties, and R. Wen, “Activation of caspase-3 in the retina of transgenic rats with the rhodopsin mutation s334ter during photoreceptor degeneration,” The Journal of Neurosciences, vol. 19, no. 12, pp. 4778–4785, 1999.

[135] A. Ray, G. J. Sun, L. Chan, N. M. Grzywacz, J. Weiland, and E. J. Lee, “Morphological alterations in retinal neurons in the S334ter-line3 transgenic rat,” Cell and Tissue Research, vol. 339, no. 3, pp. 481–491, 2010.

[136] C. L. Zhu, Y. Ji, E. J. Lee, and N. M. Grzywacz, “Spatiotemporal pattern of rod degeneration in the S334ter-line3 rat model of retinitis pigmentosa,” Cell and Tissue Research, vol. 351, no. 1, pp. 29–40, 2013.

[137] B. T. Sagdullaev, R. B. Aramant, M. J. Seiler, G. Woch, and M. A. McCall, “Retinal transplantation-induced recovery of retinotectal visual function in a rodent model of retinitis pigmentosa,” Investigative Ophthalmology & Visual Science, vol. 44, no. 4, pp. 1686–1695, 2003.

[138] B. B. Thomas, M. J. Seiler, S. R. Sadda, and R. B. Aramant, “Superior colliculus responses to light - preserved by transplantation in a slow degeneration rat model,” Experimental Eye Research, vol. 79, no. 1, pp. 29–39, 2004.

[139] Q. Peng, B. B. Thomas, R. B. Aramant, Z. Chen, S. R. Sadda, and M. J. Seiler, “Structure and function of embryonic rat retinal sheet transplants,” Current Eye Research, vol. 32, no. 9, pp. 781–789, 2007.

[140] K. Gregory-Evans, F. Chang, M. D. Hodges, and C. Y. Gregory-Evans, “Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration,” Molecular Vision, vol. 15, pp. 962–973, 2009.

[141] A. Yanai, U. O. Hafeli, A. L. Metcalfe et al., “Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles,” Cell Transplantation, vol. 21, no. 6, pp. 1137–1148, 2012.

[142] A. Santos, M. S. Humayun, E. de Juan Jr. et al., “Preservation of the inner retina in retinitis pigmentosa. A morphometric analysis,” Archives of Ophthalmology, vol. 115, no. 4, pp. 511–515, 1997.

[143] M. J. Seiler, R. B. Aramant, M. K. Jones, D. L. Ferguson, E. C. Bryda, and H. S. Keirstead, “A new immunodeficient pigmented retinal degenerate rat strain to study transplantation of human cells without immunosuppression,” Graefes Archive for Clinical and Experimental Ophthalmology, vol. 252, no. 7, pp. 1079–1092, 2014.

[144] B. Thomas, C. Shih, D. Zhu, J. Martinez, D. Hinton, and M. Humayun, A new Immunodeficient Dystrophic RCS rat Model for Transplantation Studies Using Human Derived Cells Association for Research in Vision and Ophthalmology; 2010; Seattle, WA, USA, 2016.

[145] S. Veleri, C. H. Lazar, B. Chang, P. A. Sieving, E. Banin, and A. Swaroop, “Bioloogy and therapy of inherited retinal degenerative disease: insights from mouse models,” Disease Models & Mechanisms, vol. 8, no. 2, pp. 109–129, 2015.

[146] E. V. Famiglietti and S. J. Sharpe, “Regional topography of rod and immunocytochemically characterized “blue” and “green” cone photoreceptors in rabbit retina,” Visual Neuroscience, vol. 12, no. 6, pp. 1151–1175, 1995.

[147] B. Juliusson, A. Bergstrom, P. Rohlich, B. Ehinger, T. van Veen, and A. Szil, “Complementary cone fields of the rabbit retina,” Investigative Ophthalmology & Visual Science, vol. 35, no. 3, pp. 811–818, 1994.

[148] K. W. Gjorloff, F. Ghosh, S. Andreasson, and B. Ehinger, “Standardized full-field and multifocal electroretinography in rabbits,” Investigative Ophthalmology & Visual Science, vol. 44, no. 13, pp. 2695, 2003.

[149] B. W. Jones, M. Kondo, H. Terasaki et al., “Retinal remodeling in the TgP347L rabbit, a large-eye model of retinal degeneration,” The Journal of Comparative Neurology, vol. 519, no. 14, pp. 2713–2733, 2011.

[150] S. Ueno, T. Koyasu, T. Kominami et al., “Focal cone ERGs of rhodopsin Pro347Leu transgenic rabbits,” Vision Research, vol. 91, pp. 118–123, 2013.

[151] B. J. Cho, J. M. Seo, H. G. Yu, and H. Chung, “Monocular retinal degeneration induced by intravitreal injection of sodium iodate in rabbit eyes,” Japanese Journal of Ophthalmology, vol. 60, no. 3, pp. 226–237, 2016.

[152] S. Rosch, C. Werner, F. Muller, and P. Walter, “Photoreceptor degeneration by intravitreal injection of N-methyl-N-nitrosoaur (MNU) in rabbits: a pilot study,” Graefes Archive for Clinical and Experimental Ophthalmology, vol. 255, no. 2, pp. 317–331, 2017.

[153] S. Petrus-Reurer, H. Bartuma, M. Aronsson et al., “Integration of subretinal suspension transplants of human embryonic stem cell-derived retinal pigment epithelial cells in a large-eyed model of geographic atrophy,” Investigative Ophthalmology & Visual Science, vol. 58, no. 2, pp. 1314–1322, 2017.

[154] R. Curtis, K. C. Barnett, and A. Leon, “An early-onset retinal dystrophy with dominant inheritance in the Abyssinian cat. Clinical and pathological findings,” Investigative Ophthalmology & Visual Science, vol. 28, no. 1, pp. 131–139, 1987.

[155] K. Narfstrom, “Hereditary progressive retinal atrophy in the Abyssinian cat,” The Journal of Heredity, vol. 74, no. 4, pp. 273–276, 1983.

[156] M. Menotti-Raymond, V. A. David, A. A. Schaffer et al., “Mutation in CEP290 discovered for cat model of human retinal degeneration,” The Journal of Heredity, vol. 98, no. 3, pp. 211–220, 2007.

[157] K. Narfstrom, V. David, O. Jarret et al., “Retinal degeneration in the Abyssinian and Somali cat (dAc): correlation between genotype and phenotype and dAc allele frequency in two continents,” Veterinary Ophthalmology, vol. 12, no. 5, pp. 285–291, 2009.

[158] M. W. Seeliger and K. Narfstrom, “Functional assessment of the regional distribution of disease in a cat model of hereditary retinal degeneration,” Investigative Ophthalmology & Visual Science, vol. 41, no. 7, pp. 1998–2005, 2000.

[159] L. M. Occelli, N. M. Tran, K. Narfstrom, S. Chen, and S. M. Petersen-Jones, “CrxRdy cat: a large animal model for CRX-associated Leber congenital amaurosis,” Investigative Ophthalmology & Visual Science, vol. 57, no. 8, pp. 3780–3792, 2016.

[160] H. Rah, D. J. Maggs, T. N. Blankenship, K. Narfstrom, and L. A. Lyons, “Early-onset, autosomal recessive,
progressive retinal atrophy in Persian cats,” *Investigative Ophthalmology & Visual Science*, vol. 46, no. 5, pp. 1742–1747, 2005.

[161] Y. Nan, Q. Zhang, C. Ren et al., “Functional evaluation of iodoacetic acid induced photoreceptor degeneration in the cat,” *Science China Life Sciences*, vol. 56, no. 6, pp. 524–530, 2013.

[162] M. J. Seiler, R. B. Araman, M. W. Seeliger, R. Bragadottir, M. Mahoney, and K. Narfstrom, “Functional and structural assessment of retinal sheet allograft transplantation in feline hereditary retinal degeneration,” *Veterinary Ophthalmology*, vol. 12, no. 3, pp. 158–169, 2009.

[163] K. Shibuya, M. Tomohiro, S. Sasaki, and S. Otake, “Characteristics of structures and lesions of the eye in laboratory animals used in toxicity studies,” *Journal of Toxicologic Pathology*, vol. 28, no. 4, pp. 181–188, 2015.

[164] G. G. Cloyd, M. Wyman, J. A. Shadduck, M. J. Winrow, and K. Patel, “Altered light responses of single rod photoreceptors in transgenic pigs expressing P347L or P347S rhodopsin,” *Molecular Vision*, vol. 7, pp. 6–13, 2001.

[165] T. W. Kraft, D. Allen, R. M. Petters, Y. Hao, Y. W. Peng, and F. Wong, “Altered light responses of single rod photoreceptors in transgenic pigs expressing P347L or P347S rhodopsin,” *Molecular Vision*, vol. 11, pp. 1246–1256, 2005.

[166] J. W. Kijas, A. V. Cideciyan, T. S. Aleman et al., “Progressive retinal atrophy in Persian cats,” *Ophthalmology & Visual Science*, vol. 53, no. 1, pp. 501–507, 2012.

[167] F. Ghosh, F. Wong, K. Johansson, A. Bruun, and R. M. Petters, “Transplantation of full-thickness retina in the rhodopsin transgenic pig,” *Retina (Philadelphia, Pennsylvania)*, vol. 24, no. 1, pp. 98–109, 2004.

[168] H. Klassen, J. F. Kilgaard, K. Warfvinge et al., “Photoreceptor differentiation following transplantation of allogeneic retinal progenitor cells to the dystrophic rhodopsin Pro347Leu transgenic pig,” *Stem Cells International*, vol. 2012, Article ID 939801, 9 pages, 2012.

[169] M. J. Koss, P. Falabella, F. R. Stefani et al., “Subretinal implantation of a monolayer of human embryonic stem cell-derived retinal pigment epithelium: a feasibility and safety study in Yucatan minipigs,” *Graefe’s Archive for Clinical and Experimental Ophthalmology*, vol. 254, no. 8, pp. 1553–1565, 2016.

[170] E. H. Sohn, C. Jiao, E. Kaalberg et al., “Allogenic iPSC-derived RPE cell transplants induce immune response in pigs: a pilot study,” *Scientific Reports*, vol. 5, article 11791, 2015.

[171] C. Lane, M. Boulton, and J. Marshall, “Transplantation of retinal pigment epithelium using a pars plana approach,” *Eye (London, England)*, vol. 3, Part 1, pp. 27–32, 1989.

[172] L. V. Del Priore, R. Hornbeck, H. J. Kaplan et al., “Debride-ment of the pig retinal pigment epithelium in vivo,” *Archives of Ophthalmology*, vol. 113, no. 7, pp. 939–944, 1995.

[173] N. B. Sorensen, N. Lassota, M. V. Kyhn et al., “Functional recovery after experimental RPE debridement, mERG studies in a porcine model,” *Graefe’s Archive for Clinical and Experimental Ophthalmology*, vol. 251, no. 10, pp. 2319–2325, 2013.

[174] M. G. Nicolas, K. Fujiki, K. Murayama et al., “Studies on the mechanism of early onset macular degeneration in cynomolgus (Macaca fascicularis) monkeys. I. Abnormal concentrations of two proteins in the retina,” *Experimental Eye Research*, vol. 62, no. 3, pp. 211–219, 1996.

[175] M. T. Suzuki, K. Terao, and Y. Yoshikawa, “Familial early onset macular degeneration in cynomolgus monkeys (Macaca fascicularis),” *Primates*, vol. 44, no. 3, pp. 291–294, 2003.

[176] S. Umeda, R. Ayyagari, R. Allikmets et al., “Early-onset macular degeneration with drusen in a cynomolgus monkey (Macaca fascicularis) pedigree: exclusion of 13 candidate genes and loci,” *Investigative Ophthalmology & Visual Science*, vol. 46, no. 2, pp. 683–691, 2005.

[177] S. Umeda, M. T. Suzuki, H. Okamoto et al., “Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis),” *The FASEB Journal*, vol. 19, no. 12, pp. 1683–1685, 2005.
[188] P. J. Francis, S. Wang, Y. Zhang et al., "Subretinal transplantation of forebrain progenitor cells in nonhuman primates: survival and intact retinal function," Investigative Ophthalmology & Visual Science, vol. 50, no. 7, pp. 3425–3431, 2009.

[189] K. K. Singh, M. Krawczak, W. W. Dawson, and J. Schmidtk, "Association of HTRA1 and ARMS2 gene variation with drusen formation in rhesus macaques," Experimental Eye Research, vol. 88, no. 3, pp. 479–482, 2009.

[190] C. J. Zeiss, "Animals as models of age-related macular degeneration: an imperfect measure of the truth," Veterinary Pathology, vol. 47, no. 3, pp. 396–413, 2010.

[191] W. K. Noell, "The impairment of visual cell structure by iodoacetate," Journal of Cellular and Comparative Physiology, vol. 40, no. 1, pp. 25–55, 1952.

[192] D. Fuller, R. Machemer, and R. W. Knighton, "Retinal damage produced by intraocular fiber optic light," American Journal of Ophthalmology, vol. 85, no. 4, pp. 519–537, 1978.

[193] J. M. Strazzeri, J. J. Hunter, B. D. Masella et al., "Focal damage to macaque photoreceptors produces persistent visual loss," Experimental Eye Research, vol. 119, pp. 88–96, 2014.

[194] E. W. Lankau, P. V. Turner, R. J. Mullan, and G. G. Galland, "Use of nonhuman primates in research in North America," Journal of the American Association for Laboratory Animal Science, vol. 53, no. 3, pp. 278–282, 2014.

[195] A. Varki and T. K. Altheide, "Comparing the human and chimpanzee genomes: searching for needles in a haystack," Genome Research, vol. 15, no. 12, pp. 1746–1758, 2005.

[196] H. Kamao, M. Mandai, S. Okamoto et al., "Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application," Stem Cell Reports, vol. 2, no. 2, pp. 205–218, 2014.

[197] B. B. Thomas, S. Arai, Y. Iki et al., "Retinal transplants evaluated by optical coherence tomography in photoreceptor degenerate rats," Journal of Neuroscience Methods, vol. 151, no. 2, pp. 186–193, 2006.

[198] M. J. Seiler, B. Rao, R. B. Aramant et al., "Three-dimensional optical coherence tomography imaging of retinal sheet implants in live rats," Journal of Neuroscience Methods, vol. 188, no. 2, pp. 250–257, 2010.

[199] T. Ilmarinen, H. Huidenmaa, P. Koobi et al., "Ultrathin polyimide membrane as cell carrier for subretinal transplantation of human embryonic stem cell derived retinal pigment epithelium," PLoS One, vol. 10, no. 11, article e0143669, 2015.

[200] C. R. Laver, A. L. Metcalfe, L. Szczygiel, A. Yanai, M. V. Sarunic, and K. Gregory-Evans, "Bimodal in vivo imaging provides early assessment of stem-cell-based photoreceptor engraftment," Eye (London, England), vol. 29, no. 5, pp. 681–690, 2015.

[201] S. Al-Nawaiseh, F. Thielges, Z. Liu et al., "A step by step protocol for subretinal surgery in rabbits," Journal of Visualized Experiments, vol. 115, 2016.

[202] P. Zhang, A. Zam, Y. Jian et al., "In vivo wide-field multispectral scanning laser ophthalmoscopy-optical coherence tomography mouse retinal imaging: longitudinal imaging of ganglion cells, microglia, and Müller glia, and mapping of the mouse retinal and choroidal vasculature," Journal of Biomedical Optics, vol. 20, no. 12, article 126005, 2015.

[203] R. M. Ribeiro, A. Oregon, B. Diniz et al., "In vivo detection of hESC-RPE cells via confocal near-infrared fundus reflectance," Ophthalmic Surgery, Lasers and Imaging Retina, vol. 44, no. 4, pp. 380–384, 2013.

[204] M. S. Silverman, S. E. Hughes, T. L. Valentino, and Y. Liu, "Photoreceptor transplantation: anatomic, electrophysiologic, and behavioral evidence for the functional reconstruction of retinas lacking photoreceptors," Experimental Neurology, vol. 115, no. 1, pp. 87–94, 1992.

[205] S. V. Girman, S. Wang, and R. D. Lund, "Cortical visual functions can be preserved by subretinal RPE cell grafting in RCS rats," Vision Research, vol. 43, no. 17, pp. 1817–1827, 2003.

[206] C. Gias, M. Jones, D. Keegan et al., "Preservation of visual cortical function following retinal pigment epithelium transplantation in the RCS rat using optical imaging techniques," The European Journal of Neuroscience, vol. 25, no. 7, pp. 1940–1948, 2007.

[207] L. Q. Jiang and D. Hamasaki, "Corneal electroretinographic function rescued by normal retinal pigment epithelial grafts in retinal degenerative Royal College of Surgeons rats," Investigative Ophthalmology & Visual Science, vol. 35, no. 13, pp. 4300–4309, 1994.

[208] Y. Saue, I. Pinilla, and R. D. Lund, "Partial preservation of rod and cone ERG function following subretinal injection of ARPE-19 cells in RCS rats," Vision Research, vol. 46, no. 8–9, pp. 1459–1472, 2006.

[209] T. U. Krohne, P. D. Westenskow, T. Kurihara et al., "Generation of retinal pigment epithelial cells from small molecules and OCT4 reprogrammed human induced pluripotent stem cells," Stem Cells Translational Medicine, vol. 1, no. 2, pp. 96–109, 2012.

[210] D. C. Hood, L. J. Frishman, S. Saszik, and S. Viswanathan, "Retinal origins of the primate multifocal ERG: implications for the human response," Investigative Ophthalmology & Visual Science, vol. 43, no. 5, pp. 1673–1685, 2002.

[211] S. L. Ball and H. M. Petry, "Noninvasive assessment of retinal function in rats using multifocal electroretinography," Investigative Ophthalmology & Visual Science, vol. 41, no. 2, pp. 610–617, 2000.

[212] R. Siminoff, H. O. Schwassmann, and L. Kruger, "An electrophysiological study of the visual projection to the superior colliculus of the rat," The Journal of Comparative Neurology, vol. 127, no. 4, pp. 435–444, 1966.

[213] T. J. McGill, G. T. Prusky, R. M. Douglas et al., "Discordant anatomical, electrophysiological, and visual behavioral profiles of retinal degeneration in rat models of retinal degenerative disease," Investigative Ophthalmology & Visual Science, vol. 53, no. 10, pp. 6232–6244, 2012.

[214] P. B. Yang, M. J. Seiler, R. B. Aramant et al., "Trophic factors GDNF and BDNF improve function of retinal sheet transplants," Experimental Eye Research, vol. 91, no. 5, pp. 727–738, 2010.

[215] A. Cowey and C. Franzini, "The retinal origin of uncrossed optic nerve fibres in rats and their role in visual discrimination," Experimental Brain Research, vol. 35, no. 3, pp. 443–455, 1979.

[216] B. B. Thomas, D. Shi, K. Khine, L. A. Kim, and S. R. Sadda, "Modulatory influence of stimulus parameters on optokinetic head-tracking response," Neuroscience Letters, vol. 479, no. 2, pp. 92–96, 2010.

[217] B. B. Thomas, M. J. Seiler, S. R. Sadda, P. J. Coffey, and R. B. Aramant, "Optokinetic test to evaluate visual acuity of each eye independently," Journal of Neuroscience Methods, vol. 138, no. 1-2, pp. 7–13, 2004.
K. Takahashi and S. Yamanaka, D. DiLoreto Jr., C. del Cerro, and M. del Cerro, G. Opelz, T. Kuroda, S. Yasuda, S. Kusakawa et al., G. Opelz, T. Wujciak, B. Dohler, S. Scherer, and J. Mytilineos, R. M. Douglas, N. M. Alam, B. D. Silver, T. J. McGill, W. W. J. M. Weisz, M. S. Humayun, E. De Juan Jr. et al., G. T. Prusky, K. T. Harker, R. M. Douglas, and I. Q. P. V. Algvere, T. J. McGill, B. Cottam, B. Lu et al., G. A. Peyman, K. J. Blinder, C. L. Paris, W. Alturki, N. C. Nelson Jr., and U. Desai, G. T. Prusky, P. W. West, and R. M. Douglas, S. Sugita, Y. Iwasaki, K. Makabe et al., S. Sheldon and K. Poulton, L. Berglin, P. Gouras, Y. Sheng et al., K. Warfvinge, J. F. Kiilgaard, H. Klassen et al., A. E. Cooper, J. H. Cho, S. Menges et al.,
